Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma

SHANGHAI, Aug. 12, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization

By: financialpost.com

Aug 12 2024
73
12484 Views

About Toripalimab Read More

Acronis Expands Presence in New Zealand to Meet Growing Demand for Natively Integrated Cybersecurity Solutions

Alaska Energy Metals Provides Update to Previously Announced Special Warrant and Unit Offering

Titan Suspends ESM Operations Following Flooding From Tropical Storm Debby; Annual Production Guidance Remains Unchanged

VIQ Solutions Announces Transformative Q2 2024: Significant Growth in Adjusted EBITDA

Resignations of Bangladeshi officials close to Hasina are legal, interim leader Yunus says

It Can Cost More to Power a House Than Rent It in Pakistan

Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team

Westmount Capital Partners Retained as Exclusive Financial Advisor for Township Capital

Calibre Reports Q2, 2024 and Year-To-Date Financial Results and Remains on Track to Deliver into Full Year Production Guidance While the Multi-Million Ounce Valentine Gold Mine Progresses to Construction Completion in Canada

Traction Uranium Announces the Resignation of Faizaan Lalani

Asian Futures Gain as Wall Street Remains Cautious: Markets Wrap

Methanex Helps to Ease New Zealand Power Squeeze by Idling Plant

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

Get Reliable Matka Guessing Forum with our Satta Matka Expert and Get all Matka Chart For Free.

Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma

Related